JP7771205B2 - トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体 - Google Patents
トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体Info
- Publication number
- JP7771205B2 JP7771205B2 JP2023552539A JP2023552539A JP7771205B2 JP 7771205 B2 JP7771205 B2 JP 7771205B2 JP 2023552539 A JP2023552539 A JP 2023552539A JP 2023552539 A JP2023552539 A JP 2023552539A JP 7771205 B2 JP7771205 B2 JP 7771205B2
- Authority
- JP
- Japan
- Prior art keywords
- triazol
- hydroxymethyl
- pyran
- methyl
- methoxytetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2021/055348 | 2021-03-03 | ||
| EP2021055348 | 2021-03-03 | ||
| PCT/EP2022/055224 WO2022184755A1 (en) | 2021-03-03 | 2022-03-02 | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509421A JP2024509421A (ja) | 2024-03-01 |
| JP2024509421A5 JP2024509421A5 (https=) | 2025-03-10 |
| JP7771205B2 true JP7771205B2 (ja) | 2025-11-17 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552539A Active JP7771205B2 (ja) | 2021-03-03 | 2022-03-02 | トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (https=) |
| EP (1) | EP4301748B1 (https=) |
| JP (1) | JP7771205B2 (https=) |
| KR (1) | KR20230154221A (https=) |
| CN (1) | CN116888113A (https=) |
| AU (1) | AU2022228660A1 (https=) |
| BR (1) | BR112023017624A2 (https=) |
| CA (1) | CA3209917A1 (https=) |
| CL (1) | CL2023002578A1 (https=) |
| ES (1) | ES3033422T3 (https=) |
| HR (1) | HRP20250833T1 (https=) |
| HU (1) | HUE072194T2 (https=) |
| IL (1) | IL305581A (https=) |
| MA (1) | MA63589B1 (https=) |
| MX (1) | MX2023010241A (https=) |
| PL (1) | PL4301748T3 (https=) |
| RS (1) | RS67032B1 (https=) |
| TW (1) | TWI905393B (https=) |
| UA (1) | UA130562C2 (https=) |
| WO (1) | WO2022184755A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| CN114585619B (zh) | 2019-08-29 | 2024-09-27 | 爱杜西亚药品有限公司 | α-D-吡喃半乳糖苷衍生物 |
| US12312362B2 (en) | 2020-10-06 | 2025-05-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of Alpha-D-galactopyranosides |
| EP4237419A1 (en) | 2020-11-02 | 2023-09-06 | Idorsia Pharmaceuticals Ltd | Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives |
| CN116806219A (zh) | 2021-02-09 | 2023-09-26 | 爱杜西亚药品有限公司 | 羟基杂环烷-氨甲酰基衍生物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 疾患の予防および治療用の化合物およびその使用 |
| WO2020210308A1 (en) | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2021038068A1 (en) | 2019-08-29 | 2021-03-04 | Idorsia Pharmaceuticals Ltd | Alpha-d-galactopyranoside derivatives |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| CN104755088A (zh) | 2012-10-31 | 2015-07-01 | 格莱克特生物技术公司 | 半乳凝集素-3的半乳糖苷抑制剂及其用于治疗肺纤维化的应用 |
| EP2919802A4 (en) | 2012-11-15 | 2016-09-14 | Univ Tufts | METHOD, COMPOSITIONS AND KITS FOR TREATING, MODULATING OR PREVENTING ANGIOGENESIS OR FIBROSIS IN A PATIENT USING A GALECTINE PROTEIN HEMMER |
| CA2970062C (en) | 2015-01-30 | 2023-02-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| PL3456717T3 (pl) | 2015-07-06 | 2021-10-25 | Gilead Sciences, Inc. | Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej |
| KR20200015528A (ko) | 2017-05-12 | 2020-02-12 | 갈랙틴 사이언시즈, 엘엘씨 | 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3080128A1 (en) | 2017-10-31 | 2019-05-09 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020104335A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| JP7674276B2 (ja) | 2019-07-03 | 2025-05-09 | ガレクト バイオテック エービー | ガレクチンの新規なガラクトシド阻害剤 |
| WO2021004940A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2021028323A1 (en) | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | (2-acetamidyl)thio-beta-d-galactopyranoside derivatives |
| CN114206893A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| MA56883B1 (fr) | 2019-08-15 | 2025-04-30 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
-
2022
- 2022-03-02 RS RS20250732A patent/RS67032B1/sr unknown
- 2022-03-02 PL PL22708569.3T patent/PL4301748T3/pl unknown
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en not_active Ceased
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 HR HRP20250833TT patent/HRP20250833T1/hr unknown
- 2022-03-02 UA UAA202304634A patent/UA130562C2/uk unknown
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 ES ES22708569T patent/ES3033422T3/es active Active
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko active Pending
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 EP EP22708569.3A patent/EP4301748B1/en active Active
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
- 2022-03-02 MA MA63589A patent/MA63589B1/fr unknown
- 2022-03-02 TW TW111107565A patent/TWI905393B/zh active
- 2022-03-02 JP JP2023552539A patent/JP7771205B2/ja active Active
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 HU HUE22708569A patent/HUE072194T2/hu unknown
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020519625A (ja) | 2017-05-12 | 2020-07-02 | ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＧａｌｅｃｔｉｎ Ｓｃｉｅｎｃｅｓ， ＬＬＣ | 疾患の予防および治療用の化合物およびその使用 |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
| WO2020210308A1 (en) | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| WO2021038068A1 (en) | 2019-08-29 | 2021-03-04 | Idorsia Pharmaceuticals Ltd | Alpha-d-galactopyranoside derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3209917A1 (en) | 2022-09-09 |
| PL4301748T3 (pl) | 2025-09-08 |
| WO2022184755A1 (en) | 2022-09-09 |
| TW202300146A (zh) | 2023-01-01 |
| TWI905393B (zh) | 2025-11-21 |
| MA63589B1 (fr) | 2025-07-31 |
| AU2022228660A1 (en) | 2023-10-19 |
| EP4301748A1 (en) | 2024-01-10 |
| HRP20250833T1 (hr) | 2025-09-12 |
| MX2023010241A (es) | 2023-09-12 |
| CL2023002578A1 (es) | 2024-03-22 |
| CN116888113A (zh) | 2023-10-13 |
| US20240109930A1 (en) | 2024-04-04 |
| EP4301748B1 (en) | 2025-05-07 |
| UA130562C2 (uk) | 2026-03-18 |
| JP2024509421A (ja) | 2024-03-01 |
| IL305581A (en) | 2023-10-01 |
| BR112023017624A2 (pt) | 2023-10-10 |
| EP4301748C0 (en) | 2025-05-07 |
| RS67032B1 (sr) | 2025-08-29 |
| KR20230154221A (ko) | 2023-11-07 |
| HUE072194T2 (hu) | 2025-10-28 |
| ES3033422T3 (en) | 2025-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7771205B2 (ja) | トリアゾリル－メチル置換アルファ－ｄ－ガラクトピラノシド誘導体 | |
| KR102832308B1 (ko) | 2-히드록시시클로알칸-1-카르바모일 유도체 | |
| JP7612662B2 (ja) | （ヘテロ）アリール－メチル－チオ－ベータ－ｄ－ガラクトピラノシド誘導体 | |
| KR102863667B1 (ko) | (2-아세트아미딜)티오-베타-d-갈락토피라노시드 유도체 | |
| JP7757399B2 (ja) | アルファ－ｄ－ガラクトピラノシドのスピロ誘導体 | |
| JP7612669B2 (ja) | アルファ－ｄ－ガラクトピラノシド誘導体 | |
| TWI910255B (zh) | 2-羥環烷-1-胺甲醯基衍生物 | |
| JP7844491B2 (ja) | ヒドロキシヘテロシクロアルカン－カルバモイル誘導体 | |
| HK40103132B (en) | Triazolyl‑methyl substituted alpha‑d‑galactopyranoside derivatives | |
| HK40103132A (en) | Triazolyl‑methyl substituted alpha‑d‑galactopyranoside derivatives | |
| EA049121B1 (ru) | Триазолил-метил-замещенные альфа-d-галактопиранозидные производные | |
| HK40097240A (en) | Spiro derivatives of alpha-d-galactopyranosides | |
| HK40097240B (en) | Spiro derivatives of alpha-d-galactopyranosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250227 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251007 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251105 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7771205 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |